Cancer Prevention Pharmaceuticals, Inc. (CPP), a private clinical stage biotech company developing novel therapeutics to prevent cancer and other diseases, announced today the appointment of Willene Brondum as its new Associate Vice President of Regulatory Affairs and Quality Assurance.
Ms. Brondum will lead all of CPP’s regulatory and quality assurance operations for its advancing pipeline including preparations for submission to the Food and Drug Administration (FDA) of a New Drug Application (NDA) for CPP’s lead drug CPP-1X/sul. CPP-1X/sul is currently in a pivotal Phase 3 clinical trial for adults with familial adenomatous polyposis (FAP).
Cancer Prevention Pharmaceuticals Appoints New AVP of Regulatory Affairs and Quality Assurance
